Christopher Sorli

2.0k total citations · 1 hit paper
28 papers, 1.2k citations indexed

About

Christopher Sorli is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Christopher Sorli has authored 28 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Endocrinology, Diabetes and Metabolism, 11 papers in Surgery and 11 papers in Molecular Biology. Recurrent topics in Christopher Sorli's work include Diabetes Treatment and Management (22 papers), Metabolism, Diabetes, and Cancer (11 papers) and Diabetes Management and Research (11 papers). Christopher Sorli is often cited by papers focused on Diabetes Treatment and Management (22 papers), Metabolism, Diabetes, and Cancer (11 papers) and Diabetes Management and Research (11 papers). Christopher Sorli collaborates with scholars based in United States, Canada and South Korea. Christopher Sorli's co-authors include Julie Derving Karsbøl, Jeffrey Unger, Stephen C. Bain, Thomas K. Hansen, George Tsoukas, Shin‐ichi Harashima, Ray V. Rajotte, R. Paul Robertson, Huijian Zhang and Michael B. Armstrong and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Clinical Endocrinology & Metabolism and Diabetes Care.

In The Last Decade

Christopher Sorli

28 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial

2017 496 citations Christopher Sorli, Shin‐ichi Harashima et al. The Lancet Diabetes & Endocrinology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christopher Sorli United States	13	832	443	421	286	225	28	1.2k
Michishige Terasaki Japan	15	738 0.9×	415 0.9×	345 0.8×	152 0.5×	96 0.4×	45	1.1k
Frank Ulrich Beil Germany	17	381 0.5×	398 0.9×	195 0.5×	98 0.3×	158 0.7×	37	975
Andrei I. Oprescu Canada	15	363 0.4×	406 0.9×	365 0.9×	54 0.2×	252 1.1×	22	963
Daniela Lamers Germany	11	462 0.6×	256 0.6×	259 0.6×	83 0.3×	329 1.5×	12	1.1k
Marie L.S. Lindegaard Denmark	13	400 0.5×	208 0.5×	369 0.9×	173 0.6×	209 0.9×	18	1.1k
Francesco Cremasco Italy	9	726 0.9×	296 0.7×	357 0.8×	123 0.4×	136 0.6×	13	948
Atsuko Abiko Japan	14	339 0.4×	201 0.5×	286 0.7×	42 0.1×	107 0.5×	26	795
Maria Elena Lunati Italy	11	332 0.4×	171 0.4×	159 0.4×	64 0.2×	101 0.4×	27	640
Eleonora Morini Italy	15	212 0.3×	175 0.4×	306 0.7×	47 0.2×	167 0.7×	23	699
Motofumi Sasaki Japan	13	334 0.4×	177 0.4×	202 0.5×	64 0.2×	72 0.3×	16	781

Countries citing papers authored by Christopher Sorli

Since Specialization

Citations

This map shows the geographic impact of Christopher Sorli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Sorli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Sorli more than expected).

Fields of papers citing papers by Christopher Sorli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Sorli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Sorli. The network helps show where Christopher Sorli may publish in the future.

Co-authorship network of co-authors of Christopher Sorli

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher Sorli. A scholar is included among the top collaborators of Christopher Sorli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher Sorli. Christopher Sorli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ji, Linong, Andrew Ahmann, Bo Åhrén, et al.. (2023). Proportion of participants with type 2 diabetes achieving a metabolic composite endpoint with once‐weekly semaglutide treatment versus comparators: Post hoc pooled analysis from SUSTAIN 1‐5, 7‐10 and SUSTAIN China. Diabetes Obesity and Metabolism. 26(1). 233–241. 3 indexed citations

Ji, Linong, et al.. (2023). 746-P: Semaglutide Increases the Proportion of People with T2D Achieving a Metabolic Composite Endpoint. Diabetes. 72(Supplement_1). 2 indexed citations

Hompesch, Marcus, Oakpil Han, Michael Trautmann, et al.. (2021). Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib study. BMJ Open Diabetes Research & Care. 9(1). e002208–e002208. 9 indexed citations

Yoon, Kun‐Ho, et al.. (2020). Pharmacokinetic and dose‐finding studies on efpeglenatide in patients with type 2 diabetes. Diabetes Obesity and Metabolism. 22(8). 1292–1301. 21 indexed citations

Prato, Stefano Del, Michael Trautmann, John Stewart, et al.. (2020). Efficacy and safety of once‐monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo‐controlled, 16‐week randomized dose‐finding study. Diabetes Obesity and Metabolism. 22(7). 1176–1186. 25 indexed citations

Pratley, Richard E., Michael Trautmann, Marcus Hompesch, et al.. (2019). Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study. Diabetes Obesity and Metabolism. 21(11). 2429–2439. 37 indexed citations

Rosenstock, Julio, Christopher Sorli, Michael Trautmann, et al.. (2019). Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide. Diabetes Care. 42(9). 1733–1741. 27 indexed citations

Trautmann, Michael, In Young Choi, Jung Kuk Kim, & Christopher Sorli. (2018). Preclinical Effects of Efpeglenatide, a Long-Acting Glucagon-Like Peptide-1 Receptor Agonist, Compared with Liraglutide and Dulaglutide. Diabetes. 67(Supplement_1). 8 indexed citations

Pratley, Richard E., In Young Choi, Michael Trautmann, et al.. (2018). The Effect of Efpeglenatide on Lipid Profiles and Overall Metabolism in Patients with Type 2 Diabetes and Obese Patients without Diabetes. Diabetes. 67(Supplement_1). 1 indexed citations

10.

Sorli, Christopher, Shin‐ichi Harashima, George Tsoukas, et al.. (2017). Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. The Lancet Diabetes & Endocrinology. 5(4). 251–260. 496 indexed citations breakdown →

11.

Sorli, Christopher, Stewart B. Harris, Esteban Jódar, et al.. (2017). IDegLira is Efficacious Across Baseline HbA1C Categories in Subjects with Type 2 Diabetes Uncontrolled on SU, GLP-1RA or Insulin Glargine: Analyses from Completed Phase 3b Trials. Canadian Journal of Diabetes. 41(5). S58–S58. 4 indexed citations

12.

Sorli, Christopher. (2014). Insulin Therapy in Type 2 Diabetes: A Reflection on the State of the Art Today, and the Potential Journeys Yet to Come. The American Journal of Medicine. 127(10). S1–S2. 2 indexed citations

13.

Sorli, Christopher. (2014). New Developments in Insulin Therapy for Type 2 Diabetes. The American Journal of Medicine. 127(10). S39–S48. 21 indexed citations

14.

Sorli, Christopher, et al.. (2014). Identifying and meeting the challenges of insulin therapy in type 2 diabetes. Journal of Multidisciplinary Healthcare. 7. 267–267. 63 indexed citations

15.

Sorli, Christopher, Mark Warren, David S. Oyer, et al.. (2013). Elderly Patients with Diabetes Experience a Lower Rate of Nocturnal Hypoglycaemia with Insulin Degludec than with Insulin Glargine: A Meta-Analysis of Phase IIIa Trials. Drugs & Aging. 30(12). 1009–1018. 40 indexed citations

16.

Cohen, Ricardo V., Manoel Galvão Neto, Paulo Sakai, et al.. (2013). A Pilot Study of the Duodenal-Jejunal Bypass Liner in Low Body Mass Index Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. 98(2). E279–E282. 38 indexed citations

17.

Rodríguez, Leonardo, Eliana Reyes, Almino Ramos, et al.. (2009). Pilot Clinical Study of an Endoscopic, Removable Duodenal-Jejunal Bypass Liner for the Treatment of Type 2 Diabetes. Diabetes Technology & Therapeutics. 11(11). 725–732. 89 indexed citations

18.

Markees, Thomas G., David Serreze, Nancy E. Phillips, et al.. (1999). NOD mice have a generalized defect in their response to transplantation tolerance induction.. Diabetes. 48(5). 967–974. 104 indexed citations

19.

Sairenji, Takeshi, Masanori Daibata, Christopher Sorli, et al.. (1991). Relating homology between the Epstein-Barr virus BOLF1 molecule and HLA-DQw8 ? chain to recent onset Type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 34(1). 33–39. 12 indexed citations

20.

Elliott, William L., et al.. (1989). Testing for cell surface forms of class II major histocompatibility complex antigens and I_i by radioiodination, biotinylation, and membrane immunofluorescence. American Journal of Hematology. 30(1). 4–13. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact